Currently, there are 13.15M common shares owned by the public and among those 13.03M shares have been available to trade.
Insiders at the company have transacted a total of 0 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 0 of these insider trades were purchases, accounting for 0 shares. Insider sales of the common stock occurred on 0 occasions, with total insider shares sold totaling 0 shares.
The company’s stock has a 5-day price change of 30.53% and 49.40% over the past three months. HOTH shares are trading 65.75% year to date (YTD), with the 12-month market performance up to 0.81% higher. It has a 12-month low price of $0.58 and touched a high of $3.80 over the same period. HOTH has an average intraday trading volume of 9.03 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 15.99%, 6.92%, and 29.65% respectively.
Institutional ownership of Hoth Therapeutics Inc (NASDAQ: HOTH) shares accounts for 1.86% of the company’s 13.15M shares outstanding.
It has a market capitalization of $16.31M and a beta (3y monthly) value of 0.73. The earnings-per-share (ttm) stands at -$1.40. Price movements for the stock have been influenced by the stock’s volatility, which stands at 16.14% over the week and 9.44% over the month.
Earnings per share for the fiscal year are expected to increase by 50.00%, and 32.35% over the next financial year. EPS should grow at an annualized rate of 27.42% over the next five years, compared to 15.18% over the past 5-year period.
Looking at the support for the HOTH, a number of firms have released research notes about the stock. The Benchmark Company stated their Speculative Buy rating for the stock in a research note on October 15, 2019, with the firm’s price target at $10.
